Docoh
Loading...

PRVB Provention Bio

Provention Bio, Inc. is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Biologics License Application (BLA) for teplizumab, its lead investigational drug candidate, for the delay or prevention of clinical type 1 diabetes in at-risk individuals, has been filed by the U.S. Food and Drug Administration (FDA). The Company's pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus.

PRVB stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

5 Aug 21
18 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 151.78M 151.78M 151.78M 151.78M 151.78M 151.78M
Cash burn (monthly) 9.53M (positive/no burn) 10.06M 10.56M 10.03M 8M
Cash used (since last report) 34.41M n/a 36.33M 38.13M 36.24M 28.89M
Cash remaining 117.37M n/a 115.45M 113.65M 115.54M 122.89M
Runway (months of cash) 12.3 n/a 11.5 10.8 11.5 15.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
3 Aug 21 Heidy King-Jones Stock Option Common Stock, par value $0.0001 Grant Acquire A No No 11.23 30,000 336.9K 150,000
12 May 21 Drechsler Andrew T Stock Option Common Stock, par value $0.0001 Grant Acquire A No No 6.8 139,500 948.6K 139,500
12 May 21 Hoitt Jason Stock Option Common Stock, par value $0.0001 Grant Acquire A No No 6.8 139,500 948.6K 139,500
12 May 21 Heidy King-Jones Stock Option Common Stock, par value $0.0001 Grant Acquire A No No 6.8 139,500 948.6K 139,500
12 May 21 Francisco Leon Stock Option Common Stock, par value $0.0001 Grant Acquire A No No 6.8 139,500 948.6K 139,500

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

46.9% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 130 120 +8.3%
Opened positions 28 29 -3.4%
Closed positions 18 15 +20.0%
Increased positions 47 52 -9.6%
Reduced positions 32 24 +33.3%
13F shares
Current Prev Q Change
Total value 280.27M 361M -22.4%
Total shares 29.7M 26.02M +14.2%
Total puts 639.3K 194.9K +228.0%
Total calls 521.8K 296.9K +75.7%
Total put/call ratio 1.2 0.7 +86.6%
Largest owners
Shares Value Change
BLK Blackrock 4.55M $38.33M +1.9%
Venrock Healthcare Capital Partners II 3.84M $41.05M NEW
VR Adviser 2.9M $24.47M NEW
Sessa Capital IM 2.79M $23.49M NEW
Vanguard 2.64M $22.28M -6.4%
AMGN AMGEN 2.5M $42.35M 0.0%
STT State Street 1.33M $11.2M +22.4%
Perceptive Advisors 948.48K $8M -66.7%
Geode Capital Management 940.6K $7.93M +8.6%
NTRS Northern Trust 572.6K $4.83M -4.2%
Largest transactions
Shares Bought/sold Change
Venrock Healthcare Capital Partners II 3.84M +3.84M NEW
VR Adviser 2.9M +2.9M NEW
Gilder Gagnon Howe & Co 288.07K -2.82M -90.7%
Sessa Capital IM 2.79M +2.79M NEW
Perceptive Advisors 948.48K -1.9M -66.7%
Two Sigma Advisers 12.9K -887.5K -98.6%
Two Sigma Investments 36.6K -500.72K -93.2%
683 Capital Management 298.43K -331.57K -52.6%
STT State Street 1.33M +242.73K +22.4%
Millennium Management 563.69K +227.73K +67.8%

Financial report summary

?
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: accessibility, analyzed, appointment, Ashleigh, background, BB, belief, beneficiary, broker, cap, cast, CE, cite, cited, clarification, complaint, Consolidated, Consortium, counsel, CRL, delegated, dismissed, District, Division, EMDAC, Endocrinologic, Excellence, freestanding, geographic, House, inappropriately, incentivize, longstanding, lot, outpatient, overcharged, Palmer, plaintiff, postpone, postponed, prioritization, prolonged, regular, relocate, Rescue, Restoring, resubmission, resumption, Scottish, settle, shop, Society, stayed, substudy, supervisory, talent, timeline, tying, unblinded, unclear, unspecified, variation, withdrew
Removed: adequacy, API, colony, declined, declining, England, EU, inhibitor, Janssen, Journal, largely, ninety, nonexclusive, NV, Pharmaceutica, prescribed, reaction, receptor, showed, stimulating, timeframe, Translational, UC, Vaccinology